Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-RAN Antibody (R3P21)

Catalog #:   RHF53503 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IF, IHC, WB
Accession: P62826
Overview

Catalog No.

RHF53503

Species reactivity

Human, Mouse, Rat, Monkey

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000

Target

RAN, Androgen receptor-associated protein 24, GTPase Ran, Ras-related nuclear protein, ARA24, GTP-binding nuclear protein Ran, Ras-like protein TC4

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P62826

Applications

ELISA, FCM, IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3P21

Data Image
  • Flow Cytometry
    Flow cytometric analysis of Hela cells using RAN mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of GC-7901 cells using RAN mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using RAN mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
  • Immunofluorescence
    Immunofluorescence analysis of HepG2 cells using RAN mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using RAN mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using RAN mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using RAN mouse mAb with DAB staining.
  • Western blot
    Western blot analysis using RAN mouse mAb against Hela (1), NIH/3T3 (2), A431 (3), C6 (4), Jurkat (5), Hela (6), COS7 (7), and Jurkat (8) cell lysate.
References

Amplifying tumor recognition and drug susceptibility by multivalent ApDC assembly to combat with tumor cell heterogeneity., PMID:40532654

High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with Immune checkpoint inhibitors., PMID:40520330

Immunotherapy in breast cancer: current landscape and emerging trends., PMID:40405250

Effectiveness of transcranial direct current stimulation and monoclonal antibodies acting on the CGRP as a combined treatment for migraine (TACTIC): Results of a randomized controlled trial., PMID:40384614

Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459

Wearable Photonic Device for Multiple Biomarker Sampling and Detection without Blood Draws., PMID:40326959

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial., PMID:40255182

Performance characteristics of three Brucella canis serological assays in the United States., PMID:40235569

A "CPApoptosis" nano-actuator switches immune-off solid tumors to immune-on for fueling T-cell- based immunotherapy., PMID:40213664

Targeting ALPPL2 with a novel CD89 bispecific antibody reprograms macrophages to enhance anti-tumor immunity., PMID:40209501

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma., PMID:40204067

A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors., PMID:40158720

Magnetic Nanoparticles Stabilized by Phosphorylcholine-Containing Polymer for Label-Free C-Reactive Protein Detection., PMID:40124022

Rheology of CHO Cell Suspensions and Its Effects on High-Density Cultivation Process and Bioreactor Design., PMID:40100242

Macrophage-targeting combination therapy enhances T-DXd-induced tumor regression., PMID:40088875

Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies., PMID:40056201

[Two cases of type 1 autoimmune pancreatitis diagnosed by duodenal papilla biopsy]., PMID:40050095

Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response., PMID:40035515

Periostin in Bullous Pemphigoid: A Potential Biomarker of Disease Activity and Severity., PMID:39989295

Long-term predictions of COVID-19 waves in China based on an improved SEIRS-Q model of antibody failure., PMID:39977464

Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT., PMID:39949023

CASP8 intronic expansion identified by poly-glycine-arginine pathology increases Alzheimer's disease risk., PMID:39937857

[Immunorelated Stevens-Johnson syndrome/toxic epidermolysis caused by programmed death receptor 1 inhibitors: a case report]., PMID:39914838

Long-Term Lipid Lowering With Evolocumab in Older Individuals., PMID:39909681

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer., PMID:39879779

Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial., PMID:39874903

Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell combo Stent vs. biolimus eluting absorbable polymer coated biomatrix alpha stent in patients undergoing percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for randomized trials with clinical outcome (SORT OUT) XI trial., PMID:39870125

L1CAM+ extracellular vesicles derived from the serum of adolescents with major depressive disorder induce depression-like phenotypes in adolescent mice., PMID:39842672

RNF128 deficiency in macrophages promotes colonic inflammation by suppressing the autophagic degradation of S100A8., PMID:39809743

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period., PMID:39762664

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial., PMID:39739622

Re-evaluation of the relationship between PrPc expression and patient prognosis in primary esophageal squamous cell carcinoma and primary hepatocellular carcinoma., PMID:39732816

A study of autoimmune thyroid disease in pregnant women and its effect on fetal and maternal outcome., PMID:39722948

Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab., PMID:39718423

OmpH is Involved in the Decrease of Acinetobacter baumannii Biofilm by the Antimicrobial Peptide Cec4., PMID:39664965

The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series., PMID:39660186

Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study., PMID:39652286

Prevalence of immunity to hepatitis B in NCAA athletes., PMID:39601800

Protective Impact of Influenza Vaccination on Healthcare Workers., PMID:39591140

The consequences of SARS-CoV-2 within-host persistence., PMID:39587352

Immunogenicity and Safety of COVID-19 Vaccines in Patients with Lung Cancer: Results of a Systematic Review and Meta-Analysis., PMID:39557036

Assessment of Single-Cycle M-Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS-CoV-2 Immunogen Delivery., PMID:39526809

Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial., PMID:39501485

Autocatalysis-Integrated Bioorthogonal (Poly)Catalyst-Linked Immunosorbent Assay for Living Cell Membrane Antigens., PMID:39468940

Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)., PMID:39442013

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China., PMID:39426385

Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis., PMID:39417358

Effects on molecular interactions of hollow gold nanoparticles and antibody for sensitizing P24 antigen determination., PMID:39315032

Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis., PMID:39305187

Ferritin nanoparticle-based Nipah virus glycoprotein vaccines elicit potent protective immune responses in mice and hamsters., PMID:39293542

Datasheet

Document Download

Anti-RAN Antibody (R3P21).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-RAN Antibody (R3P21) [RHF53503]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only